Abstract
CD4+ Foxp3+ regulatory T cell (Treg) therapy in organ transplantation is being examined in phase I/II studies. However, Treg fate after infusion remains unknown, and concerns persist that they may convert into effector cells. We recently described a novel method for generating alloantigen-reactive Tregs using the phosphodiesterase 3b (PDE3b) inhibitor cilostamide (cilos Tregs). We hypothesized that cilos Tregs would exhibit superior phenotypic and functional stability compared with transforming growth factor β-generated Tregs (TGFβ Tregs).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
